ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "antiphospholipid syndrome"

  • Abstract Number: 2550 • 2013 ACR/ARHP Annual Meeting

    Predictive Markers Of Preeclampsia During Pregnancy In Patients With Systemic Erithematosus LUPUS and / Or Antiphospholipid Syndrome

    Esther Rodriguez-Almaraz1, Elena Gonzalo-Gil2, Ignacio Herráiz3, Paula I Gómez-Arriaga3, Paloma Vallejo3, Elena A López-Jiménez4, María Galindo Izquierdo1 and Alberto Galindo Izquierdo3, 1Department of Rheumatology. Hospital Universitario 12 de Octubre, Madrid, Spain, 2Grupo de Investigación en Enfermedades Inflamatorias y Autoinmunes, Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain, 3Fetal Medicine Unit, Department of Obstetrics and Gynecology. Hospital Universitario 12 de Octubre., Madrid, Spain, 4Department of Biochemistry. Hospital Universitario 12 de Octubre., Madrid, Spain

    Background/Purpose: Patients with systemic lupus erythematosus (SLE) have an increased risk of preeclampsia (PE), which can be confused with lupus nephritis. Our objective was to…
  • Abstract Number: 2456 • 2012 ACR/ARHP Annual Meeting

    Pro-Inflammatory and Pro-Thrombotic Markers in Persistently Antiphospholipid Antibody-Positive Patients with/without Systemic Lupus Erythematosus

    Gurjot Basra1, Doruk Erkan2, Rohan Willis1, JoAnn Vega3, Ana Laura Carrera Marin4, Patricia Ruiz Limon1, Vijaya L. Murthy1, Shraddha Jatwani1, Neha Dang1, Emilio B. Gonzalez1 and Silvia S. Pierangeli4, 1Rheumatolgoy/Dept Int Med, University of Texas Medical Branch, Galveston, TX, 2Rheumatology, Hospital for Special Surgery, New York, NY, 3Research, Hospital for Special Surgery, New York, NY, 4Rheumatology/Dept Int Med, University of Texas Medical Branch, Galveston, TX

    Background/Purpose: Pro-inflammatory/thrombotic biomarkers (BMR), which are associated with aPL-mediated pathogenic effects in vitro/vivo, are also increased in aPL-positive patients. Here we examined whether those BMR…
  • Abstract Number: 2458 • 2012 ACR/ARHP Annual Meeting

    The Estimated Prevalence of Antiphospholipid Antibodies in General Population Patients with Pregnancy Loss, Stroke, Myocardial Infarction, and Deep Vein Thrombosis

    Laura Andreoli1, Alessandra Banzato2, Cecilia B. Chighizola3, Guillermo J. Pons-Estel4, Guilherme Ramires de Jesus5, Michael D. Lockshin6, Doruk Erkan7 and On Behalf of APS Action8, 1Rheumatology and Clinical Immunology, University of Brescia, Brescia, Italy, 2Department of Cardiac Thoracic and Vascular Sciences, Department of Cardiac Thoracic and Vascular Sciences, University of Padua, Padua, Italy, 3Rheumatology, Istituto Auxologico Italiano, University of Milan, Milan, Italy, 4Servicio de Enfermedades Autoinmunes, Department of Autoimmune Diseases, Institut Clìnic de Medicina i Dermatologia, Hospital Clìnic, Barcelona, Spain, 5Department of Obstetrics, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, 6Rheumatology, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, 7Rheumatology, Hospital for Special Surgery, New York, NY, 8APS ACTION, New York, NY

    Background/Purpose: AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking (APS ACTION) is an international research network that has been created specifically to design and…
  • Abstract Number: 2459 • 2012 ACR/ARHP Annual Meeting

    Efficacy of Aspirin for the Prevention of the First Thrombo-Embolic Events in Patients with Antiphospholipid Antibodies: A Metanalysis of Literature Data

    Laurent Arnaud1, Alexis Mathian2, Amelia Ruffatti3, Maria Tecktonidou4, Ricard Cervera5, Ricardo Forastiero6, Vittorio Pengo7, Marc Lambert8, Stephane Zuily9, Denis Wahl9 and Zahir Amoura1, 1Internal Medicine, Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, 2Department of Internal Medicine 2. Referal center for SLE/APS, Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, 3Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Padua, Padua, Italy, 4First Department of Internal Medicine, School of Medicine, National University of Athens, Athens, Greece, 5Autoimmune Diseases, Hospital Clínic of Barcelona, Barcelona, Spain, 6Favaloro University, Argentina, 7Clinical Cardiology, Department of Cardiac Thoracic and Vascular Sciences, University of Padova, Padova, Italy, 8Medecine Interne Lilloise, Internal Medicine University Lille Hospital, Lille, Lille, France, 9Regional Competence Center For Rare Vascular And Systemic Autoimmune Diseases, Nancy University Hospital, Université de Lorraine & INSERM U961, Vandoeuvre-Les-Nancy, France

    Background/Purpose: Whether aspirin is needed in patients with antiphospholipid antibodies (aPL+) for prevention of a first thrombotic event is controversial. The aim of this metaanalysis…
  • Abstract Number: 2460 • 2012 ACR/ARHP Annual Meeting

    Dual Antiplatelet Therapy As Prophylaxis of Recurrent Arterial Thrombosis in Patients with antiphospholipid Syndrome

    Yuichiro Fujieda1, Olga Amengual2, Toshiyuki Watanabe1, Michihito Kono2, Yusaku Kanetsuka2, Takashi Kurita2, Toshio Odani1, Kotaro Otomo1, Toshiyuki Bohgaki2, Tetsuya Horita2, Shinsuke Yasuda2 and Tatsuya Atsumi2, 1Medicine II, Hokkaido University, Sapporo, Japan, 2Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan

    Background/Purpose: Arterial thrombosis (AT) is a major clinicalmanifestation of the antiphospholipid syndrome (APS). A number of studies have evaluated the rate of recurrent thromboembolism, including…
  • Abstract Number: 2404 • 2012 ACR/ARHP Annual Meeting

    Cardiovascular Disease Prevention Counseling Program for Systemic Lupus Erythematosus and/or Antiphospholipid Antibody Positive Patients: Two-Year Preliminary Analysis of Diet and Exercise Habits

    Virginia Haiduc1, Monica C. Richey1, Sotiria Everett2, Aeshita Dwivedi1, Lisa Konstantellis1, Hassan Ghomrawi3 and Doruk Erkan4, 1Rheumatology, Hospital for Special Surgery, New York, NY, 2Hospital for Special Surgery, New York, NY, 3Healthcare Research and Policy, Weill Cornell Medical College, New York, NY, 4Rheumatology Dept, Hospital for Special Surgery, New York, NY

    Background/Purpose: SLE patients have high rate of cardiovascular events due to increased prevalence of traditional cardiovascular disease (CVD)- and other lupus-related thrombosis risk factors. In…
  • Abstract Number: 1737 • 2012 ACR/ARHP Annual Meeting

    Diffuse Alveolar Hemorrhage Caused by Primary Antiphospholipid Syndrome

    Rodrigo Cartin-Ceba1, Tobias Peikert2, Karina Keogh2, Steven R. Ytterberg3, Aneel Ashrani4 and Ulrich Specks2, 1Pulmonary and Critical Care, Mayo Clinic, Rochester, MN, 2Mayo Clinic, Rochester, MN, 3Rheumatology Division, Mayo Clinic, Rochester, MN, 4Hematology, Mayo Clinic, Rochester, MN

    Background/Purpose: Diffuse alveolar hemorrhage (DAH) is an uncommon but severe complication of primary antiphospholipid syndrome (APS). The available literature is limited to very few case…
  • Abstract Number: 1740 • 2012 ACR/ARHP Annual Meeting

    Impairment of Quality of Life in Patients with Antiphospholipid Syndrome

    Stephane Zuily1, Francis Guillemin2, Veronique Regnault3, Pierre Kaminsky4, Patrick Mismetti5, Jacques Ninet6, Nicolas Baillet7, Nadine Magy-Bertrand8, Bernard Lorcerie9, Jean-Louis Pasquali10, Thomas Lecompte11, Anne-Christine Rat12 and Denis Wahl13, 1CHU de Nancy, Vascular Medicine Division and Regional Competence Center For Rare Vascular And Systemic Autoimmune Diseases, Nancy, F-54000, France; Inserm, UMR_S 1116, Nancy, F-54000, France; Université de Lorraine, Nancy, F-54000, France, Nancy, France, 2INSERM, Centre d'Investigation Clinique - Epidémiologie Clinique (CIC-EC) CIE6, Nancy, France, 3Inserm, UMR_S 1116, Nancy, F-54000, France; Université de Lorraine, Nancy, F-54000, France; CHU de Nancy, Contrat d’interface, Nancy, F-54000, France, Nancy, France, 4Internal Medicine, Orphan disease Unit, Nancy, France, 5CHU Saint-Etienne, Unité de Pharmacologie Clinique, Groupe de Recherche sur la Thrombose (EA 3065), Saint Etienne, France, 6Department of Nephrology and Internal Medicine, Hôpital Edouard Herriot, Lyon, France, Lyon, France, 7Hôpitaux civils de Colmar, Service de Médecine interne, Colmar, France, 8CHU Jean-Minjoz, Service de médecine interne et immunologie clinique, Besançon, France, 9Hopital Du Bocage, Service de Médecine Interne et Immunologie Clinique, Dijon, France, 10Strasbourg University, Hospital, CNRS UPR 3572, Strasbourg, France, 11Inserm, UMR_S 1116, Nancy, F-54000, France; Université de Lorraine, Nancy, F-54000, France; CHU de Nancy, Haematology Laboratory, Nancy, F-54000, France; Division of Haematology, HUG, Geneva, Switzerland (current address), Geneva, Switzerland, 12Université de Lorraine, INSERM, CIC-EC CIE6, Rheumatology, Epidemiology, Nancy, France, 13Nancy University Hospital and INSERM U961, Vascular medicine division and Regional Competence Center For Rare Vascular And Systemic Autoimmune Diseases, Nancy, France

    Background/Purpose : Quality of life (QoL) is an important outcome in clinical care especially in patients with chronic disease such as systemic lupus erythematosus (SLE).…
  • Abstract Number: 1724 • 2012 ACR/ARHP Annual Meeting

    Pandemic Influenza Immunization in Primary Antiphospholipid Syndrome (PAPS): A Trigger to Autoantibody Production?

    Danielle M. Medeiros1, Cleonice Bueno2, Ana Cristina M. Ribeiro1, Ana L. G. Calich1, Karina Rossi Bonfiglioli3, Vilma S. Viana1, Jozelio F. Carvalho4, Clovis Artur Silva5 and Eloisa Bonfá6, 1Division of Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 2Division of Rheumatology, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, 3Divison of Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 4Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 5Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genova, Italy, 6Rheumatology Division, University of Sao Paulo, Sao Paulo, Brazil

    Background/Purpose: There are scarce data suggesting that pandemic influenza vaccination may induce antiphospholipid (APL) autoantibodies in inflammatory rheumatic diseases, particularly in systemic lupus erythematosus patients.…
  • Abstract Number: 1728 • 2012 ACR/ARHP Annual Meeting

    Purified IgG From Antiphospholipid Syndrome Patients with Pregnancy Morbidity Alone Inhibit Trophoblast Migration and Activate a TLR4 MyD88 Independent Pathway

    Katie Poulton1, Vera Ripoll1, Charis Pericleous2, Yiannis Ioannou3, Anisur Rahman4 and Ian Giles4, 1Centre for Rheumatology Research, Division of Medicine, University College London, London, United Kingdom, 2Centre for Rheumatology, Division of Medicine, Centre for Rheumatology, University College London, London, United Kingdom, 3Arthritis Research UK Centre for Adolescent Rheumatology at University College London, Great Ormond Street Hospital and UCLH, University College London, London, United Kingdom, 4Centre for Rheumatology Research,Rayne Institute, 4th Floor, University College London, London, United Kingdom

    Background/Purpose: Patients with the Antiphospholipid Syndrome (APS) have circulating antiphospholipid antibodies which cause vascular thrombosis (VT) and/or pregnancy morbidity (PM). Previously we have shown that…
  • Abstract Number: 1733 • 2012 ACR/ARHP Annual Meeting

    Effect of Hydroxychloroquine (HCQ) On the Annexin A5 Resistance Assay (AnxA5-RA) in Antiphospholipid Antibody (aPL)-Positive Patients: Preliminary Results of an Ongoing Prospective Study

    Alana B. Levine1, Jacob H. Rand2, Xiao Xuan Wu3, JoAnn Vega4, Glendalee Ramon1, Stephen L. Lyman4, Doruk Erkan1 and Michael D. Lockshin5, 1Rheumatology, Hospital for Special Surgery, New York, NY, 2Department of Pathology; Hematology Laboratories, Montefiore Medical Center, Bronx, NY, 3Pathology; Hematology Laboratories, Montefiore Medical Center, Bronx, NY, 4Research, Hospital for Special Surgery, New York, NY, 5Rheumatology, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY

    Background/Purpose: One proposed mechanism of aPL-mediated thrombosis is disruption of the AnxA5 shield, allowing initiation of coagulation reactions on phospholipid surfaces.  The AnxA5-RA measures the…
  • Abstract Number: 1734 • 2012 ACR/ARHP Annual Meeting

    Clinical Accuracy for Diagnosis of Antiphospholipid Syndrome in Systemic Lupus Erythematosus: Evaluation of 23 Possible Combinations of Antiphospholipid Antibody Specificities

    Savino Sciascia1, Veronica Murru1, Giovanni Sanna2, Dario Roccatello3, Munther A. Khamashta4 and Maria Laura Bertolaccini1, 1Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom, 2Louise Coote Lupus Unit, St. Thomas' Hospital, London, United Kingdom, 3Department of Rare, Immunologic, Hematologic and Immunohematologic Diseases, Centro di Immunopatologia e Documentazione su Malattie rare, Torino, Italy, 4Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom

    Background/Purpose: The clinical accuracy of testing for antiphospholipid antibody (aPL) both, as individual tests and/or in combination, is still being investigated. We aimed to identify…
  • Abstract Number: 1735 • 2012 ACR/ARHP Annual Meeting

    Independent Validation of the Antiphospholipid Score (aPL-S) for the Diagnosis of Antiphospholipid Syndrome (APS)

    Savino Sciascia1, Maria Laura Bertolaccini1, Dario Roccatello2 and Munther A. Khamashta3, 1Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom, 2Department of Rare, Immunologic, Hematologic and Immunohematologic Diseases, Centro di Immunopatologia e Documentazione su Malattie rare, Torino, Italy, 3Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom

    Background/Purpose: The so called “antiphospholipid score (aPL-S)” was recently developed and validated (1). This score was shown to be a useful quantitative index for diagnosing…
  • « Previous Page
  • 1
  • …
  • 17
  • 18
  • 19
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology